|
1
|
Sylvester RJ, van der Meijden AP,
Oosterlinck W, et al: Predicting recurrence and progression in
individual patients with stage Ta T1 bladder cancer using EORTC
risk tables: A combined analysis of 2596 patients from seven EORTC
trials. Eur Urol. 49:466–475. 2006. View Article : Google Scholar
|
|
2
|
Vaux DL and Silke J: Mammalian
mitochondrial IAP binding proteins. Biochem Biophys Res Commun.
304:499–504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wei Y, Fan T and Yu M: Inhibitor of
apoptosis proteins and apoptosis. Acta Biochim Biophys Sin
(Shanghai). 40:278–288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Srinivasula SM and Ashwell JD: IAPs:
what’s in a name? Mol Cell. 30:123–135. 2008.
|
|
5
|
Dubrez-Daloz L, Dupoux A and Cartier J:
IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle.
7:1036–1046. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
LaCasse EC, Mahoney DJ, Cheung HH, et al:
IAP-targeted therapies for cancer. Oncogene. 27:6252–6275. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dohi T, Okada K, Xia F, et al: An IAP-IAP
complex inhibits apoptosis. J Biol Chem. 279:34087–34090. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheung HH, Plenchette S, Kern CJ, et al:
The RING domain of cIAP1 mediates the degradation of RING-bearing
inhibitor of apoptosis proteins by distinct pathways. Mol Biol
Cell. 19:2729–2740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Conze DB, Albert L, Ferrick DA, et al:
Posttranscriptional downregulation of c-IAP2 by the ubiquitin
protein ligase c-IAP1 in vivo. Mol Cell Biol. 25:3348–3356.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vucic D and Fairbrother WJ: The inhibitor
of apoptosis proteins as therapeutic targets in cancer. Clin Cancer
Res. 13:5995–6000. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Che X, Yang D, Zong H, et al: Nuclear
cIAP1 overexpression is a tumor stage- and grade-independent
predictor of poor prognosis in human bladder cancer patients. Urol
Oncol. 30:450–456. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gazzaniga P, Gradilone A, Giuliani L, et
al: Expression and prognostic significance of LIVIN, SURVIVIN and
other apoptosis-related genes in the progression of superficial
bladder cancer. Ann Oncol. 14:85–90. 2003. View Article : Google Scholar
|
|
13
|
Li M, Song T, Yin ZF, et al: XIAP as a
prognostic marker of early recurrence of nonmuscular invasive
bladder cancer. Chin Med J. 120:469–473. 2007.PubMed/NCBI
|
|
14
|
Yin W, Chen N, Zhang Y, et al: Survivin
nuclear labeling index: a superior biomarker in superficial
urothelial carcinoma of human urinary bladder. Mod Pathol.
19:1487–1497. 2006.PubMed/NCBI
|
|
15
|
Mehrotra S, Languino LR, Raskett CM, et
al: IAP regulation of metastasis. Cancer Cell. 17:53–64. 2010.
View Article : Google Scholar
|
|
16
|
Jin HS, Lee DH, Kim DH, et al: cIAP1,
cIAP2, and XIAP act cooperatively via nonredundant pathways to
regulate genotoxic stress-induced nuclear factor-κB activation.
Cancer Res. 69:1782–1791. 2009.PubMed/NCBI
|
|
17
|
Yang D, Song X, Zhang J, et al:
Therapeutic potential of siRNA-mediated combined knockdown of the
IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24
cells. Acta Biochim Biophys Sin (Shanghai). 42:137–144. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rodríguez-Berriguete G, Fraile B, de
Bethencourt FR, et al: Role of IAPs in prostate cancer progression:
immunohistochemical study in normal and pathological (benign
hyperplastic, prostatic intraepithelial neoplasia and cancer) human
prostate. BMC Cancer. 10:182010.
|
|
19
|
Lopes RB, Gangeswaran R, McNeish IA, et
al: Expression of the IAP protein family is dysregulated in
pancreatic cancer cells and is important for resistance to
chemotherapy. Int J Cancer. 120:2344–2352. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Samuel T, Okada K, Hyer M, et al: cIAP1
Localizes to the nuclear compartment and modulates the cell cycle.
Cancer Res. 65:210–218. 2005.PubMed/NCBI
|
|
21
|
Stauber RH, Mann W and Knauer SK: Nuclear
and cytoplasmic survivin: molecular mechanism, prognostic, and
therapeutic potential. Cancer Res. 67:5999–6002. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Amantana A, London CA, Iversen PL and Devi
GR: X-linked inhibitor of apoptosis protein inhibition induces
apoptosis and enhances chemotherapy sensitivity in human prostate
cancer cells. Mol Cancer Ther. 3:699–707. 2004.
|
|
23
|
Gill C, Dowling C, O’Neill AJ and Watson
RW: Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate
cancer cell susceptibility to apoptosis. cell survival and
proliferation. Mol Cancer. 8:392009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vischioni B, van der Valk P, Span SW, et
al: Expression and localization of inhibitor of apoptosis proteins
in normal human tissues. Hum Pathol. 37:78–86. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma L, Huang Y, Song Z, et al: Livin
promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway.
Cell Death Differ. 13:2079–2088. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen F, Yang D, Wang S, et al: Livin
regulates prostate cancer cell invasion by impacting the NF-κB
signaling pathway and the expression of FN and CXCR4. IUBMB Life.
64:274–283. 2012.PubMed/NCBI
|
|
27
|
Xi RC, Biao WS and Gang ZZ: Significant
elevation of survivin and livin expression in human colorectal
cancer: inverse correlation between expression and overall
survival. Onkologie. 34:428–432. 2011. View Article : Google Scholar
|
|
28
|
Li WQ, Li XL, Wang GP and Fu B: Gene
expression of livin and survivin in adult patients with acute
lymphoblastic leukemia and its clinical significance. Zhongguo Shi
Yan Xue Ye Xue Za Zhi. 19:921–925. 2011.(In Chinese).
|
|
29
|
Peng XH, Karna P, O’Regan RM, et al:
Down-regulation of inhibitor of apoptosis proteins by deguelin
selectively induces apoptosis in breast cancer cells. Mol
Pharmacol. 71:101–111. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Choi S, Lew KL, Xiao H, et al: D,
L-Sulforaphane-induced cell death in human prostate cancer cells is
regulated by inhibitor of apoptosis family proteins and Apaf-1.
Carcinogenesis. 28:151–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
